Sun Pharma has said that its group firm Taro is going to fully acquire Canada’s Thallion Pharmaceuticals for 2.7 million Canadian dollar.

Sun Pharma has said in a regulatory filing that Taro Pharmaceuticals Inc (Canada) has entered into an agreement to acquire all of the issue and outstanding shares of Thallion Pharmaceuticals, a Canadian Pharmaceutical corporation.

It added that the cost of all-cash acquisition will be Canadian dollar 2.3 million with an additional amount of Canadian dollar 0.4 million due at the completion of an additional pre-clinical animal study or April 1, 2019.

Read EquityPandit’s Technical Analysis on Nifty Pharma